Insider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells 3,084 Shares of Stock

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) insider Suma Krishnan sold 3,084 shares of the stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $151.01, for a total value of $465,714.84. Following the transaction, the insider directly owned 1,509,445 shares of the company's stock, valued at $227,941,289.45. The trade was a 0.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Suma Krishnan also recently made the following trade(s):

• On Wednesday, July 16th, Suma Krishnan sold 1,389 shares of Krystal Biotech stock. The shares were sold at an average price of $150.00, for a total value of $208,350.00.
• On Wednesday, July 16th, Suma Krishnan sold 1,529 shares of Krystal Biotech stock. The shares were sold at an average price of $150.00, for a total value of $229,350.00.
• On Tuesday, July 15th, Suma Krishnan sold 3,036 shares of Krystal Biotech stock. The shares were sold at an average price of $150.98, for a total value of $458,375.28.
• On Monday, July 14th, Suma Krishnan sold 13,400 shares of Krystal Biotech stock. The shares were sold at an average price of $150.30, for a total value of $2,014,020.00.
• On Monday, July 14th, Suma Krishnan sold 13,435 shares of Krystal Biotech stock. The shares were sold at an average price of $150.30, for a total value of $2,019,280.50.
• On Thursday, July 10th, Suma Krishnan sold 6,927 shares of Krystal Biotech stock. The shares were sold at an average price of $150.27, for a total value of $1,040,920.29.
• On Thursday, July 10th, Suma Krishnan sold 6,800 shares of Krystal Biotech stock. The shares were sold at an average price of $150.28, for a total value of $1,021,904.00.
• On Wednesday, July 9th, Suma Krishnan sold 200 shares of Krystal Biotech stock. The shares were sold at an average price of $150.14, for a total value of $30,028.00.

Krystal Biotech Stock Performance

Shares of KRYS traded up $2.35 during midday trading on Wednesday, hitting $150.08. 280,630 shares of the stock were exchanged, compared to its average volume of 287,303. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $219.34. The stock has a fifty day simple moving average of $135.75 and a 200 day simple moving average of $156.11. The firm has a market cap of $4.34 billion, a P/E ratio of 36.08 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The firm had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. As a group, equities research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on KRYS. Chardan Capital reaffirmed a "buy" rating and issued a $219.00 price target on shares of Krystal Biotech in a report on Wednesday, May 7th. Citigroup reaffirmed a "neutral" rating and issued a $176.00 price target (up previously from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. Guggenheim cut their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, HC Wainwright reissued a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research note on Tuesday, June 24th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $213.75.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Raymond James Financial Inc. purchased a new position in Krystal Biotech in the fourth quarter valued at $15,989,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Krystal Biotech by 31.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,054 shares of the company's stock valued at $948,000 after purchasing an additional 1,440 shares during the period. Swiss National Bank boosted its holdings in Krystal Biotech by 8.4% in the fourth quarter. Swiss National Bank now owns 42,400 shares of the company's stock valued at $6,642,000 after purchasing an additional 3,300 shares during the period. Commonwealth Equity Services LLC boosted its holdings in Krystal Biotech by 4.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 4,866 shares of the company's stock valued at $762,000 after purchasing an additional 190 shares during the period. Finally, Cibc World Markets Corp purchased a new position in Krystal Biotech in the fourth quarter valued at $364,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.